US 12,030,879 B2
Sulfonyl acetamides as NLRP3 inhibitors
Matthew Cooper, Cambridge (GB); David Miller, Cambridge (GB); Jimmy Van Wiltenburg, Groningen (NL); Johannes Wilhem Georg Meissner, Groningen (NL); Jochem Theodoor Van Herpt, Groningen (NL); Zhou Min Lion, Groningen (NL); Jonathan Shannon, Nottingham (GB); and Stephen St-Gallay, Nottingham (GB)
Assigned to INFLAZOME LIMITED, Dublin (IE)
Appl. No. 16/977,445
Filed by Inflazome Limited, Dublin (IE)
PCT Filed Mar. 1, 2019, PCT No. PCT/EP2019/055146
§ 371(c)(1), (2) Date Sep. 1, 2020,
PCT Pub. No. WO2019/166629, PCT Pub. Date Sep. 6, 2019.
Claims priority of application No. 1803412 (GB), filed on Mar. 2, 2018; application No. 1803413 (GB), filed on Mar. 2, 2018; application No. 1900291 (GB), filed on Jan. 9, 2019; application No. 1902319 (GB), filed on Feb. 20, 2019; and application No. 1902320 (GB), filed on Feb. 20, 2019.
Prior Publication US 2021/0002274 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 9/00 (2006.01); C07D 213/64 (2006.01); C07D 213/643 (2006.01); C07D 213/71 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07F 5/02 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 9/0014 (2013.01); C07D 213/64 (2013.01); C07D 213/643 (2013.01); C07D 213/71 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07F 5/027 (2013.01)] 23 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Q is selected from O or S;
R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton;
R2 is a 6-membered cyclic group substituted at the α and α′ positions, wherein the substituent at the α-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the α-ring atom of the cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, wherein the substituent at the α′-position comprises at least one carbon atom, and wherein the cyclic group may optionally be further substituted;
R3 is hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2;
R4 is hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or
R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated cyclic group, wherein the cyclic group may optionally be substituted; and
R5 is independently optionally substituted C1-C4 alkyl.